【０００１】[0001]
【産業上の利用分野】本発明は、医薬用ドリンク剤等の
配合成分等として有用なγ−オリザノールの水への可溶
化方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for solubilizing .gamma.-oryzanol in water, which is useful as a compounding ingredient for medical drinks and the like.
【０００２】[0002]
【従来の技術】γ−オリザノールは自律神経に作用し
て、視床下部におけるカテコールアミンの増加、脳下垂
体前葉の刺激、微小循環血流増加等の作用があることが
知られている。近年、体力増強、疲労回復、活力増進等
を目的とした医薬用ドリンク剤には、かかるγ−オリザ
ノールを配合する試みがなされている。2. Description of the Related Art It is known that γ-oryzanol acts on autonomic nerves to increase catecholamines in the hypothalamus, stimulate the anterior pituitary gland, increase microcirculatory blood flow and the like. In recent years, attempts have been made to blend such γ-oryzanol into a medicinal drink for the purpose of enhancing physical strength, recovering from fatigue, enhancing vitality, and the like.
【０００３】しかしながら、γ−オリザノールは水に対
して難溶性であるため、医薬用ドリンク剤等の液剤中に
配合するためには、水への可溶化処理を行わなくてはな
らなかった。However, since γ-oryzanol is poorly soluble in water, a solubilization treatment in water had to be carried out in order to mix it in a liquid drug such as a medicinal drink.
【０００４】一般的なγ−オリザノールの水への可溶化
方法としては、適当な界面活性剤を使用する方法が挙げ
られる。しかしγ−オリザノールの水可溶化のためには
界面活性剤を多量に使用する必要があるため、調製され
た製剤は界面活性剤特有の味と臭いが残って服用しにく
いという欠点があった。As a general method for solubilizing γ-oryzanol in water, a method using an appropriate surfactant can be mentioned. However, in order to solubilize γ-oryzanol in water, it is necessary to use a large amount of a surfactant, and thus the prepared preparation has a drawback that the taste and odor peculiar to the surfactant remain and it is difficult to take.
【０００５】そこで、かかる欠点を克服する目的で従来
様々な研究がなされており、例えば、γ−オリザノール
にショ糖脂肪酸エステルとエタノールを混合する方法
（特開平2-149597号公報）、γ−オリザノールにショ糖
脂肪酸エステルとポリオキシエチレン硬化ヒマシ油を混
合する方法（特開平2-149598号公報）、γ−オリザノー
ルとシクロデキストリンとを反応させる方法（特公昭62
-46555号公報）、γ−オリザノールとアミド系化合物と
を反応させる方法（特公昭63-57439号公報）等が行われ
てきたが、これら従来の方法はいずれも煩雑であった
り、またエタノールを多量に使用している等の問題があ
った。Therefore, various studies have been made in the past with the aim of overcoming such drawbacks, for example, a method of mixing sucrose fatty acid ester and ethanol with γ-oryzanol (Japanese Patent Laid-Open No. 2-149597), γ-oryzanol. A method of mixing sucrose fatty acid ester with polyoxyethylene hydrogenated castor oil (JP-A-2-149598) and a method of reacting γ-oryzanol with cyclodextrin (JP-B-62)
-46555), a method of reacting γ-oryzanol with an amide compound (Japanese Patent Publication No. 63-57439), etc., but all of these conventional methods are complicated or ethanol There was a problem such as using a large amount.
【０００６】[0006]
【発明が解決しようとする課題】従って、少量の界面活
性剤で容易にγ−オリザノールを水に可溶化する方法の
開発が望まれていた。Therefore, it has been desired to develop a method for easily solubilizing γ-oryzanol in water with a small amount of a surfactant.
【０００７】[0007]
【課題を解決するための手段】かかる実情において、本
発明者は鋭意研究をおこなった結果、可溶化剤として非
イオン性界面活性剤とビタミンＥ類を併用すればエタノ
ールの存在なしにγ−オリザノールが水に溶解し、かつ
味と香りも良好であることを見出し本発明を完成した。Under such circumstances, the present inventor has conducted diligent research and, as a result, if a nonionic surfactant and vitamin Es were used in combination as a solubilizing agent, γ-oryzanol was obtained without the presence of ethanol. The present invention has been completed by finding out that is soluble in water and has a good taste and aroma.
【０００８】すなわち、本発明はγ−オリザノール１重
量部、非イオン性界面活性剤２〜60重量部、ビタミンＥ
類１〜５重量部及び水50〜1000重量部を混合することを
特徴とするγ−オリザノールの水への可溶化方法を提供
するものである。That is, the present invention comprises 1 part by weight of γ-oryzanol, 2 to 60 parts by weight of a nonionic surfactant, and vitamin E.
The present invention provides a method for solubilizing γ-oryzanol in water, which comprises mixing 1 to 5 parts by weight of the compounds with 50 to 1000 parts by weight of water.
【０００９】本発明において用いられる非イオン性界面
活性剤としては、例えばポリオキシエチレン硬化ヒマシ
油、ポリオキシエチレンソルビタン脂肪酸エステル、シ
ョ糖脂肪酸エステル、ポリオキシエチレン−ポリオキシ
プロピレン縮合物等が挙げられる。本発明においてはこ
れらのうちポリオキシエチレン硬化ヒマシ油が好まし
く、特に酸化エチレンの平均付加モル数が30〜120のポ
リオキシエチレン硬化ヒマシ油が好ましい。Examples of the nonionic surfactant used in the present invention include polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, sucrose fatty acid ester, polyoxyethylene-polyoxypropylene condensate and the like. . In the present invention, polyoxyethylene hydrogenated castor oil is preferable, and polyoxyethylene hydrogenated castor oil having an average added mole number of ethylene oxide of 30 to 120 is particularly preferable.
【００１０】これらの非イオン性界面活性剤の使用量は
γ−オリザノール１重量部に対して２〜60重量部、特に
５〜20重量部が好ましい。使用量が２重量部未満では、
γ−オリザノールが充分に溶解せず、一方、60重量部を
超えると、界面活性剤特有の味と臭いが残るため好まし
くない。The amount of these nonionic surfactants used is preferably 2 to 60 parts by weight, more preferably 5 to 20 parts by weight, relative to 1 part by weight of γ-oryzanol. If the amount used is less than 2 parts by weight,
γ-Oryzanol is not sufficiently dissolved, while if it exceeds 60 parts by weight, the taste and odor peculiar to the surfactant remain, which is not preferable.
【００１１】また、ビタミンＥ類としては、天然ビタミ
ンＥはもちろん、酢酸トコフェロールも用いることがで
きる。本発明におけるビタミンＥ類の使用量はγ−オリ
ザノール１重量部に対して１〜５重量部、特に２〜４重
量部が好ましい。使用量が１重量部未満では、γ−オリ
ザノールが充分に溶解せず、一方、５重量部を超える
と、著しい白濁がみられる。As vitamin Es, not only natural vitamin E but also tocopherol acetate can be used. The amount of vitamin Es used in the present invention is preferably 1 to 5 parts by weight, and particularly preferably 2 to 4 parts by weight, relative to 1 part by weight of γ-oryzanol. When the amount used is less than 1 part by weight, γ-oryzanol is not sufficiently dissolved, while when it exceeds 5 parts by weight, remarkable white turbidity is observed.
【００１２】また、水の使用量はγ−オリザノール１重
量部に対して50〜1000重量部、特に50〜200重量部が好
ましい。The amount of water used is preferably 50 to 1000 parts by weight, more preferably 50 to 200 parts by weight, relative to 1 part by weight of γ-oryzanol.
【００１３】本発明可溶化方法を、実施するには、非イ
オン性界面活性剤及びビタミンＥ類を混合しておき、こ
の系にγ−オリザノールを添加し、次いで水を添加する
のが好ましい。可溶化時の温度は特に限定されないが50
〜90℃が好ましい。In order to carry out the solubilization method of the present invention, it is preferable to mix a nonionic surfactant and vitamin Es, add γ-oryzanol to this system, and then add water. The temperature during solubilization is not particularly limited, but 50
~ 90 ° C is preferred.
【００１４】かくして可溶化されたγ−オリザノール水
性溶液は均一な液状を呈し、そのままで各種液状医薬
品、液状食品等の配合成分として使用できるが、更に緩
衝剤、各種糖類、他の薬効成分等を添加することもでき
る。The thus solubilized γ-oryzanol aqueous solution exhibits a uniform liquid state and can be used as it is as a compounding ingredient of various liquid pharmaceuticals, liquid foods, etc., and further, a buffering agent, various sugars, other medicinal ingredients and the like. It can also be added.
【００１５】[0015]
【発明の効果】本発明の可溶化方法を用いればエタノー
ルを使用することなく、γ−オリザノールを少量の界面
活性剤で容易に水に可溶化することができ、得られたγ
−オリザノール水性溶液は各種液状医薬品、液状食品
等、特に医薬用ドリンク剤の配合成分として有用であ
る。The solubilization method of the present invention allows γ-oryzanol to be easily solubilized in water with a small amount of a surfactant without using ethanol.
The oryzanol aqueous solution is useful as a compounding ingredient of various liquid medicines, liquid foods, etc., especially pharmaceutical drinks.
【００１６】[0016]
【実施例】次に実施例を挙げて本発明を更に説明する
が、本発明はこれによって何ら限定されるものではな
い。EXAMPLES Next, the present invention will be further described with reference to examples, but the present invention is not limited thereto.
【００１７】実施例１〜３、比較例１〜３ 以下の表１に示す組成のドリンク剤を下記製法に従って
調製し、γ−オリザノールの水への溶解状態を目視で判
定した。結果を表２に示す。Examples 1 to 3 and Comparative Examples 1 to 3 Drink preparations having the compositions shown in Table 1 below were prepared according to the following production method, and the dissolution state of γ-oryzanol in water was visually determined. The results are shown in Table 2.
【００１８】[0018]
【表１】 （組成） γ−オリザノール 表２に示す量 クエン酸 500mg クエン酸ナトリウム 200mg 果糖 30ｇ ショ糖 10ｇ ビタミンＥ 表２に示す量 ポリオキシエチレン硬化ヒマシ油(60) 表２に示す量 精製水 全体を500ml
とする量[Table 1] (Composition) γ-oryzanol Amount shown in Table 2 Citric acid 500 mg Sodium citrate 200 mg Fructose 30 g Sucrose 10 g Vitamin E Amount shown in Table 2 Polyoxyethylene hydrogenated castor oil (60) Amount shown in Table 2 Purified water 500 ml for the whole
Amount to
【００１９】（製法）ポリオキシエチレン硬化ヒマシ油
(60)にビタミンＥを加え、加熱して約75℃に保ち、よく
混合する。次いでγ−オリザノールを加えて、攪拌しな
がら完全に溶解する。その後、加熱した精製水にて全体
を200mlとする。高速攪拌機で攪拌し、γ−オリザノー
ルの水性溶液を得る。この水性溶液10mlにクエン酸、ク
エン酸ナトリウム、果糖、ショ糖を加えて溶かし、精製
水にて全体を500mlとする。(Production Method) Polyoxyethylene hydrogenated castor oil
Vitamin E is added to (60), heated and kept at about 75 ° C, and mixed well. Then, γ-oryzanol is added and completely dissolved while stirring. Then, make up to 200 ml with heated purified water. Stir with a high speed stirrer to obtain an aqueous solution of γ-oryzanol. To 10 ml of this aqueous solution, add citric acid, sodium citrate, fructose and sucrose to dissolve, and make up to 500 ml with purified water.
【００２０】（評価基準） ○：透明又はやや曇った状態で沈殿なし。 ×：可溶化できなかった。(Evaluation Criteria) ◯: No precipitation in a transparent or slightly cloudy state. X: Could not be solubilized.
【００２１】[0021]
【表２】[Table 2]
【００２２】表２の結果から明らかな如く、ポリオキシ
エチレン硬化ヒマシ油(60)だけでは水に溶解しないγ−
オリザノールも、ビタミンＥを添加することによって溶
解する。また、γ−オリザノールに対するビタミンＥの
量は１〜５重量倍が好ましいことがわかる。ビタミンＥ
がγ−オリザノールの５重量倍を超えて多量に使用（比
較例３）すると、著しく白濁する。As is clear from the results of Table 2, polyoxyethylene hydrogenated castor oil (60) alone does not dissolve in water.
Oryzanol is also dissolved by adding Vitamin E. It is also understood that the amount of vitamin E with respect to γ-oryzanol is preferably 1 to 5 times by weight. Vitamin E
When it is used in a large amount in excess of 5 times the weight of γ-oryzanol (Comparative Example 3), it becomes extremely cloudy.
【００２３】実施例４〜７、比較例４〜５ ビタミンＥ及びポリオキシエチレン硬化ヒマシ油(60)の
量を表３の通りにする以外は実施例１〜３及び比較例１
〜３と同様にドリンク剤を調製し、γ−オリザノールの
水への溶解状態を目視で判定した。結果を表３に示す。
尚、表３には、得られた液の臭いの有無も併せて記載し
た。Examples 4-7, Comparative Examples 4-5 Examples 1-3 and Comparative Example 1 except that the amounts of Vitamin E and polyoxyethylene hydrogenated castor oil (60) are as shown in Table 3.
A drink preparation was prepared in the same manner as in Examples 1 to 3, and the dissolution state of γ-oryzanol in water was visually determined. The results are shown in Table 3.
In addition, Table 3 also shows whether or not the obtained liquid has an odor.
【００２４】[0024]
【表３】[Table 3]
【００２５】表３の結果から明らかな如く、γ−オリザ
ノールは非イオン性界面活性剤とビタミンＥを添加する
ことによって水に溶解する。また、γ−オリザノールに
対するポリオキシエチレン硬化ヒマシ油(60)の量は２重
量倍以上が好ましいことがわかる。また、ポリオキシエ
チレン硬化ヒマシ油(60)を多量に使用（比較例５）する
と臭いがあった。As is clear from the results of Table 3, γ-oryzanol is dissolved in water by adding a nonionic surfactant and vitamin E. Further, it is understood that the amount of polyoxyethylene hydrogenated castor oil (60) with respect to γ-oryzanol is preferably 2 times by weight or more. Further, when a large amount of polyoxyethylene hydrogenated castor oil (60) was used (Comparative Example 5), it had an odor.
【００２６】実施例８ 下記組成のドリンク剤を実施例１〜７と同様にして製造
したところ、組成中のγ−オリザノールは均一に溶解
し、安定な水性溶液が得られた。Example 8 When a drink having the following composition was produced in the same manner as in Examples 1 to 7, γ-oryzanol in the composition was uniformly dissolved and a stable aqueous solution was obtained.
【００２７】[0027]
【表４】 （組成） γ−オリザノール ２ｇ クエン酸 500mg クエン酸ナトリウム 200mg 果糖 30ｇ ショ糖 10ｇ ビタミンＥ ５ｇ ポリオキシエチレンソルビタン脂肪酸 エステル* 10ｇ 精製水 全体を500ml
とする量 ＊：ポリオキシエチレンソルビタンモノオレエート(約2
0)[Table 4] (Composition) γ-Oryzanol 2 g Citric acid 500 mg Sodium citrate 200 mg Fructose 30 g Sucrose 10 g Vitamin E 5 g Polyoxyethylene sorbitan fatty acid ester* 10 g Purified water 500 ml
Amount *: Polyoxyethylene sorbitan monooleate (about 2
0)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18980293AJPH0741422A (en) | 1993-07-30 | 1993-07-30 | Method for solubilizing gamma-oryzanol in water |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18980293AJPH0741422A (en) | 1993-07-30 | 1993-07-30 | Method for solubilizing gamma-oryzanol in water |
| Publication Number | Publication Date |
|---|---|
| JPH0741422Atrue JPH0741422A (en) | 1995-02-10 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18980293AWithdrawnJPH0741422A (en) | 1993-07-30 | 1993-07-30 | Method for solubilizing gamma-oryzanol in water |
| Country | Link |
|---|---|
| JP (1) | JPH0741422A (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002020268A (en)* | 2000-07-10 | 2002-01-23 | Takeda Chem Ind Ltd | Internal liquid containing fat-soluble substance |
| JP2007508296A (en)* | 2003-05-22 | 2007-04-05 | リポシン・インコーポレーテッド | Pharmaceutical composition and dosage form for hydrophobic drug administration |
| JP2008120748A (en)* | 2006-11-14 | 2008-05-29 | Taisho Pharmaceutical Co Ltd | γ-oryzanol solubilized liquid composition |
| JP2012214444A (en)* | 2011-03-25 | 2012-11-08 | Taisho Pharmaceutical Co Ltd | Loxoprofen-containing external preparation |
| US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US9757390B2 (en) | 2010-11-30 | 2017-09-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| CN109567142A (en)* | 2019-01-24 | 2019-04-05 | 中南林业科技大学 | A kind of gamma oryzanol embedding liquid and preparation method and instant milk powder and preparation method |
| US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
| US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
| US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
| US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002020268A (en)* | 2000-07-10 | 2002-01-23 | Takeda Chem Ind Ltd | Internal liquid containing fat-soluble substance |
| JP2007508296A (en)* | 2003-05-22 | 2007-04-05 | リポシン・インコーポレーテッド | Pharmaceutical composition and dosage form for hydrophobic drug administration |
| JP2011252015A (en)* | 2003-05-22 | 2011-12-15 | Lipocine Inc | Pharmaceutical composition and dosage form for administration of hydrophobic drug |
| JP2008120748A (en)* | 2006-11-14 | 2008-05-29 | Taisho Pharmaceutical Co Ltd | γ-oryzanol solubilized liquid composition |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
| US10881671B2 (en) | 2010-11-30 | 2021-01-05 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9949985B2 (en) | 2010-11-30 | 2018-04-24 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US10226473B2 (en) | 2010-11-30 | 2019-03-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9943527B2 (en) | 2010-11-30 | 2018-04-17 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US11364250B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US10716794B2 (en) | 2010-11-30 | 2020-07-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US10799513B2 (en) | 2010-11-30 | 2020-10-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9757390B2 (en) | 2010-11-30 | 2017-09-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US10973833B2 (en) | 2010-11-30 | 2021-04-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US11364249B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US11311555B2 (en) | 2010-11-30 | 2022-04-26 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
| JP2012214444A (en)* | 2011-03-25 | 2012-11-08 | Taisho Pharmaceutical Co Ltd | Loxoprofen-containing external preparation |
| US11298365B2 (en) | 2014-08-28 | 2022-04-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
| US11872235B1 (en) | 2014-08-28 | 2024-01-16 | Lipocine Inc. | Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters |
| US12171770B1 (en) | 2014-08-28 | 2024-12-24 | Lipocine Inc. | Bioavailable solid state (17-beta)-hydroxy-4-androsten-3-one esters |
| US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
| CN109567142A (en)* | 2019-01-24 | 2019-04-05 | 中南林业科技大学 | A kind of gamma oryzanol embedding liquid and preparation method and instant milk powder and preparation method |
| Publication | Publication Date | Title |
|---|---|---|
| KR860001503B1 (en) | Ivermectin Solubility Method | |
| JPH0741422A (en) | Method for solubilizing gamma-oryzanol in water | |
| JPH05506458A (en) | Nutritional supplement containing vitamin E | |
| JPS6025918A (en) | Aqueous solution containing fat-soluble drug | |
| NL8000129A (en) | TRANSDERMAL MEDICATION SYSTEM FOR ISOSORBIDINE INITRATE. | |
| JP3523260B2 (en) | Fenbendazole formulation | |
| JPH11255640A (en) | Emulsified preparation for external use for skin | |
| JP2939082B2 (en) | Stable vitamin A palmitate and vitamin E solubilized eye drops | |
| JPH0764884B2 (en) | Cyclodextrin composition | |
| JPH01135715A (en) | Stable aqueous solutions of fat-soluble substances | |
| HUE027718T2 (en) | Oil-in-water emulsion of mometasone and propylene glycol | |
| JPH047722B2 (en) | ||
| EP0003682A1 (en) | Process for solubilizing an insoluble drug and an aqueous solution prepared by this process | |
| JPH0242814B2 (en) | ||
| JPH10179086A (en) | Oil solubilized solution, food and drink containing plant sterol, and method for producing the same | |
| US5955456A (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
| JPH0536412B2 (en) | ||
| HU199289B (en) | Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid | |
| JPH0725735A (en) | Gargle | |
| JPH1171269A (en) | Oral liquid pharmaceutical preparation | |
| JPH05139955A (en) | Stable instillation | |
| JP4475405B2 (en) | Pharmaceutical composition | |
| JP3438264B2 (en) | Method for preparing stable vitamin A solubilized aqueous eye drops | |
| JP4586336B2 (en) | Aqueous solution containing fat-soluble substances | |
| FI96742B (en) | Single-phase gel composition containing minoxidil and process for producing it |
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination | Free format text:JAPANESE INTERMEDIATE CODE: A300 Effective date:20001003 |